We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 1.04% | 48.50 | 47.00 | 47.50 | 47.75 | 45.75 | 47.75 | 2,975,500 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.42 | 134.01M |
TIDMAVCT
Avacta Group PLC
29 July 2019
29 July 2019
Avacta Group plc
("Avacta", the "Company" or the "Group")
Avacta's Chief Executive Officer to Present at the Solebury Trout European Biotech Investor Day in New York
Avacta Group plc (AIM: AVCT), a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer(R) platform, is pleased to announce that its Chief Executive Officer, Dr Alastair Smith, will present at the European Biotech Investor Day in New York City in the New York Times building on Thursday, August 1(st) organised by Solebury Trout and sponsored by Goodwin LLC, Deutsche Bank, H.C. Wainwright and Nasdaq.
Alastair's presentation will discuss the Company's drug development pipeline based on the combination of Affimer immunotherapies with tumour targeted chemotherapy aimed at addressing the lack of a durable response to current immunotherapies experienced by most cancer patients.
The presentation will be made available on the Company's website: https://www.avacta.com/investors/documents.
- Ends -
For further information from Avacta Group plc, please contact:
Avacta Group plc Tel: +44 (0) 844 414 0452 Alastair Smith, Chief Executive www.avacta.com Officer Tony Gardiner, Chief Financial Officer finnCap Ltd (Nominated Adviser Tel: +44 (0) 207 220 0500 and Joint Broker) www.finncap.com Geoff Nash / Giles Rolls - Corporate Finance Tim Redfern - ECM Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 WG Partners (Joint Broker) www.wgpartners.co.uk Nigel Birks / Nigel Barnes David Wilson / Claes Spang Turner Pope Investments Tel: +44 (0) 203 621 4120 James Pope / Ben Turner www.turnerpope.com Yellow Jersey PR (Financial Media and IR) Tel: +44 (0)7764 947 137 Sarah Hollins Tel: +44 (0)7544 275 882 Harriet Jackson avacta@yellowjerseypr.com Zyme Communications (Trade and Tel: +44 (0)7787 502 947 Regional Media) katie.odgaard@zymecommunications.com Katie Odgaard
About Avacta Group plc - https://www.avacta.com
Avacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer(R) biotherapeutics and tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients.
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal's immune response, to generate new antibodies; poor specificity in many cases; large size and cost.
Avacta's proprietary targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments.
By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first programme into the clinic in the first half of 2020.
Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., and a deal with LG Chem worth up to $310m, and actively seeks to license its proprietary platforms in a range of therapeutic areas. The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
About the European Biotech Investor Day
The European Biotech Investor Day in NYC, features privately-held and EU-listed biotechnology companies representing the "Next Wave of Opportunities" emerging from Europe.
Participating companies offer compelling or novel approaches to addressing a range of indications. To inquire about Solebury Trout or to attend the event, please contact Thomas Hoffman at thoffmann@troutgroup.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRALLFSSDTIRFIA
(END) Dow Jones Newswires
July 29, 2019 02:01 ET (06:01 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions